Avicenna is providing Canon with its FDA-approved CINA Head triage AI software for neurovascular emergencies, which detects two of the leading causes of stroke — intracranial hemorrhage (ICH) and large vessel occlusion (LVO) — from CT-scan imaging.
Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow, according to Avicenna.
CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the U.S., with 96% accuracy, 91.4% sensitivity and 97.5% specificity, the company noted. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.
“Our partnership with Avicenna demonstrates our commitment to providing our customers with AI solutions that help them to improve the quality of care,” said Toshiki Kato, GM of healthcare IT for Canon Medical Systems, in a news release. “With its proven ability to help radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care, CINA Head is exactly the kind of innovative solution that we want to offer clinicians.”
“Our partnership with a medical imaging modality leader like Canon Medical Systems is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase,” added Avicenna CEO Cyril Di Grandi. “We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond.”